Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion. March 18, 2024 07:00 AM Eastern Daylight Time.

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James ...

Dr. James Kelly, MD is a renowned refractive surgeon specialist and comprehensive ophthalmologist in NYC and the tri state area. He is a Diplomate of the American Board of Ophthalmology qualifying ...

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 Oragenics Wed, Feb 5, 2025, 8:15 AM 3 ...

Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James" Jim" Kelly, Neurologist ...

Kelly Vision Dr. Ashley Brissette Dr. James Kelly and Dr. Ashley Brissette NEW YORK , NY, UNITED STATES, March 10, 2025 /EINP. Tuesday, 02 January 2024 12:17 GMT.

We apologize, but this video has failed to load. Try refreshing your browser, or tap here to see other videos from our team. Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II ...

SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...